ESRRA and breast cancer: Based on the results above, in which we demonstrated that the activation of ERRα by cholesterol or mevalonate was able to confer resistance to chemotherapy, as well as to promote breast cancer aggressiveness, we assessed the prognostic value of ERRα in patients with breast cancer (all breast cancer subtypes).